Home › Research › Biomarkers
Blood-based AT(N) biomarkers for Alzheimer's disease and frontotemporal lobar degeneration in Latin America
Caviedes A, Cabral-Miranda F, Orellana P, Hernández H, Henríquez F, Gonzalez-Gomez R, Pizarro M, Migeot J, Ochoa-Rosales C, Gonzalez-Silva C, Marin-Diaz N, Coronel-Oliveros C, et al.. Nature Aging, 2026-02-13
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Dementia diagnosis increasingly relies on blood-based biomarkers, yet their performance in diverse populations remains insufficiently characterized. Latin America, with substantial genetic and environmental heterogeneity, is particularly underrepresented in biomarker research. Here we show that plasma AT(N) biomarkers can distinguish Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD) in a multinational Latin American cohort (N = 605). Aβ 42 /Aβ 40 amyloid-β ratios were reduced and levels of phosphorylated tau (p-tau217, p-tau181) and neurofilament light chain (NfL) were elevated in both disorders, with NfL showing greater increases in FTLD. Classification models achieved receiver operating characteristic areas under the curve (ROC AUCs) of 83% for AD and 88% for FTLD. Meta-analyses confirmed consistency across countries, and these markers correlated with executive, memory and global cognitive impairment. Biomarker alterations combined with disease-specific neuroimaging patterns and cognitive measures further improved accuracy (ROC AUCs of 89% for AD and 95% for FTLD). These findings indicate that plasma AT(N) biomarkers, combined with neuroimaging and clinical assessments, can enhance dementia diagnosis across diverse Latin American populations.
What this study adds
Evidence grade: Moderate
This is a cross-sectional study of 605 participants. In a Latin American cohort, plasma AT(N) biomarkers helped distinguish Alzheimer's disease from frontotemporal lobar degeneration, especially when combined with imaging and cognitive tests. Reported effect size: AUC 83% (AD) and 88% (FTLD) with plasma biomarkers; 89% and 95% with imaging and cognition added.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Caviedes, A., Cabral-Miranda, F., Orellana, P., Hernández, H., Henríquez, F., Gonzalez-Gomez, R., et al. (2026). Blood-based AT(N) biomarkers for Alzheimer's disease and frontotemporal lobar degeneration in Latin America. Nature Aging. https://doi.org/10.1038/s43587-025-01061-3
Vancouver
Caviedes A, Cabral-Miranda F, Orellana P, Hernández H, Henríquez F, Gonzalez-Gomez R, et al. Blood-based AT(N) biomarkers for Alzheimer's disease and frontotemporal lobar degeneration in Latin America. Nature Aging. 2026. doi:10.1038/s43587-025-01061-3. PMID: 41688826.
BibTeX
@article{caviedes2026-41688826,
author = {Caviedes, A. and Cabral-Miranda, F. and Orellana, P. and Hernández, H. and Henríquez, F. and Gonzalez-Gomez, R. and Pizarro, M. and Migeot, J. and Ochoa-Rosales, C. and Gonzalez-Silva, C. and Marin-Diaz, N. and Coronel-Oliveros, C. and others},
title = {{Blood-based AT(N) biomarkers for Alzheimer's disease and frontotemporal lobar degeneration in Latin America}},
journal = {Nature Aging},
year = {2026},
doi = {10.1038/s43587-025-01061-3},
pmid = {41688826},
url = {https://doi.org/10.1038/s43587-025-01061-3}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- These findings indicate that plasma AT(N) biomarkers, combined with neuroimaging and clinical assessments, can enhance dementia diagnosis across diverse Latin American populations.
Why it matters
In a Latin American cohort, plasma AT(N) biomarkers helped distinguish Alzheimer's disease from frontotemporal lobar degeneration, especially when combined with imaging and cognitive tests. This is a diagnostic study, not a treatment or cure.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designcross-sectional
- Participants605
- Effect sizeAUC 83% (AD) and 88% (FTLD) with plasma biomarkers; 89% and 95% with imaging and cognition added
- Evidence strengthModerate
Limitations
Cross-sectional design cannot capture progression or biomarker trajectories; no direct comparison with CSF or PET was available, so overlap with LATE cannot be excluded; individual comorbidities were sparsely reported and collapsed to a binary variable; and Latin America's genetic, environmental and sociocultural heterogeneity challenges direct application of biomarker thresholds.
How this study scored 57/100
Published in a leading specialty journal, and it is a snapshot of people at one point in time. Scored zero for randomized / blinded because the record does not state it. We have no data on free to read, so that was left out: it earned 56 of the 98 points we could judge it on, which is 57 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Nature Aging) |
| Journal's citation record | 1 / 4 | Nature Aging: journal h-index 103 (OpenAlex, 2026-10-29) |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 2 / 4 | 605 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 2 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 4 / 6 | Cited 9.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Maira Okada de Oliveira: h-index 24 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 65 institution(s) in 16 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41688826) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 56 / 98 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 56 of the 98 points we could judge it on is 57 out of 100. |
| Total | 57 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 31.
Related studies in Biomarkers from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.